99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer

PSMA Clinical Trial

Official title: 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET

Status Recruiting

Clinical Trial Summary

99mTc-QULIC-5-P1 is a new radiotracer targeting PSMA, which is promising as an excellent imaging agent applicable to PSMA positive prostate cancer. This study will investigate the safety, biodistribution and potential usefulness of 99mTc-QULIC-5-P1 SPECT imaging for the diagnosis of lesions in PSMA positive prostate cancer.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Prostate Cancer Stage
• Prostatic Neoplasms
• SPECT

• NCT number: NCT06419348
• Study type: Interventional
• Source: First Affiliated Hospital of Chongqing Medical University
• Contact: Xiaoyang Zhang, PhD
• Phone: 023-89011755
• Email: zhangxy@mail.bnu.edu.cn
• Status: Recruiting
• Phase: Early Phase 1
• Start date: May 20, 2024
• Completion date: December 31, 2026